BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:BHC • CA0717341071
5.66 USD
-0.04 (-0.7%)
At close: Feb 4, 2026
5.66 USD
0 (0%)
After Hours: 2/4/2026, 8:05:13 PM
Taking everything into account, BHC scores 4 out of 10 in our fundamental rating. BHC was compared to 191 industry peers in the Pharmaceuticals industry. While BHC is still in line with the averages on profitability rating, there are concerns on its financial health. BHC is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year BHC was profitable.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC always reported negative net income.
- BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- BHC has a Return On Assets of 1.35%. This is amongst the best in the industry. BHC outperforms 80.10% of its industry peers.
- The Return On Invested Capital of BHC (7.44%) is better than 84.82% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 12.83%.
- The 3 year average ROIC (5.98%) for BHC is below the current ROIC(7.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROIC | 7.44% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
1.3 Margins
- BHC has a better Profit Margin (3.61%) than 80.10% of its industry peers.
- BHC has a better Operating Margin (20.68%) than 87.96% of its industry peers.
- In the last couple of years the Operating Margin of BHC has grown nicely.
- With a decent Gross Margin value of 70.67%, BHC is doing good in the industry, outperforming 78.01% of the companies in the same industry.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% |
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
- BHC has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BHC has more shares outstanding
- The debt/assets ratio for BHC has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 0.24, we must say that BHC is in the distress zone and has some risk of bankruptcy.
- BHC's Altman-Z score of 0.24 is in line compared to the rest of the industry. BHC outperforms 47.64% of its industry peers.
- BHC has a debt to FCF ratio of 19.41. This is a negative value and a sign of low solvency as BHC would need 19.41 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 19.41, BHC is doing good in the industry, outperforming 75.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 0.24 |
ROIC/WACC1.1
WACC6.79%
2.3 Liquidity
- BHC has a Current Ratio of 1.30. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of BHC (1.30) is worse than 76.44% of its industry peers.
- BHC has a Quick Ratio of 1.30. This is a bad value and indicates that BHC is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.97, BHC is not doing good in the industry: 78.01% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 1.33% over the past year.
- The Earnings Per Share has been decreasing by -2.91% on average over the past years.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 5.86%.
- Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 2.28% on average per year.
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
3.2 Future
- The Earnings Per Share is expected to decrease by -3.58% on average over the next years.
- BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.40% yearly.
EPS Next Y5.12%
EPS Next 2Y6.66%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BHC is valuated cheaply with a Price/Earnings ratio of 1.48.
- 98.95% of the companies in the same industry are more expensive than BHC, based on the Price/Earnings ratio.
- BHC is valuated cheaply when we compare the Price/Earnings ratio to 28.25, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 1.32 indicates a rather cheap valuation of BHC.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaper than 98.95% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BHC to the average of the S&P500 Index (27.50), we can say BHC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.48 | ||
| Fwd PE | 1.32 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaper than 94.76% of the companies in the same industry.
- BHC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BHC is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.94 | ||
| EV/EBITDA | 6.62 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y6.66%
EPS Next 3Y-1.71%
5. Dividend
5.1 Amount
- BHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.66
-0.04 (-0.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-18 2026-02-18/amc
Inst Owners45.78%
Inst Owner Change-3.82%
Ins Owners10.79%
Ins Owner Change-0.55%
Market Cap2.10B
Revenue(TTM)10.03B
Net Income(TTM)362.00M
Analysts48.89
Price Target7.35 (29.86%)
Short Float %1.54%
Short Ratio2.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.24%
Min EPS beat(2)-7.07%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-8.49%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)4
Avg EPS beat(8)-3.92%
EPS beat(12)7
Avg EPS beat(12)-2.32%
EPS beat(16)8
Avg EPS beat(16)-5.93%
Revenue beat(2)2
Avg Revenue beat(2)0.5%
Min Revenue beat(2)0.36%
Max Revenue beat(2)0.64%
Revenue beat(4)3
Avg Revenue beat(4)-0.05%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)0.64%
Revenue beat(8)6
Avg Revenue beat(8)0.85%
Revenue beat(12)9
Avg Revenue beat(12)1.1%
Revenue beat(16)9
Avg Revenue beat(16)-0.08%
PT rev (1m)-0.56%
PT rev (3m)0.39%
EPS NQ rev (1m)-0.59%
EPS NQ rev (3m)2.39%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)0.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.48 | ||
| Fwd PE | 1.32 | ||
| P/S | 0.21 | ||
| P/FCF | 1.94 | ||
| P/OCF | 1.39 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.62 |
EPS(TTM)3.82
EY67.49%
EPS(NY)4.29
Fwd EY75.78%
FCF(TTM)2.92
FCFY51.64%
OCF(TTM)4.06
OCFY71.75%
SpS27.04
BVpS-1.52
TBVpS-44.98
PEG (NY)0.29
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | N/A | ||
| ROCE | 9.41% | ||
| ROIC | 7.44% | ||
| ROICexc | 7.91% | ||
| ROICexgc | 35.57% | ||
| OM | 20.68% | ||
| PM (TTM) | 3.61% | ||
| GM | 70.67% | ||
| FCFM | 10.81% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.98%
ROIC(5y)5.41%
ROICexc(3y)6.26%
ROICexc(5y)5.63%
ROICexgc(3y)44%
ROICexgc(5y)37.54%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexgc growth 3Y34.27%
ROICexgc growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 6.2 | ||
| Cap/Depr | 34.45% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.65% | ||
| Profit Quality | 299.45% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 0.24 |
F-Score7
WACC6.79%
ROIC/WACC1.1
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
EPS Next Y5.12%
EPS Next 2Y6.66%
EPS Next 3Y-1.71%
EPS Next 5Y-3.58%
Revenue 1Y (TTM)5.86%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
Revenue Next Year6.13%
Revenue Next 2Y5.11%
Revenue Next 3Y3.03%
Revenue Next 5Y-0.4%
EBIT growth 1Y18.58%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year16.54%
EBIT Next 3Y4.34%
EBIT Next 5Y-1.3%
FCF growth 1Y21.39%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y34.83%
OCF growth 3Y3.85%
OCF growth 5Y1.25%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 2 / 10.